贝伐珠单抗联合伊立替康治疗恶性胶质瘤的不良血管事件风险:系统综述与Meta分析
该系统综述与Meta分析检索Cochrane Library、Embase和PubMed至2018年6月,纳入6项研究,评估成人恶性胶质瘤患者接受贝伐珠单抗联合伊立替康治疗的不良血管事件风险。结果显示联合伊立替康不显著影响全身不良事件风险(OR 1.17,95%CI 0.43-3.18),血液毒性、血小板减少和高血压风险相似,但血栓形成风险更高(OR 3.23,95%CI 1.47-7.12)。
要点
- 贝伐珠单抗联合伊立替康不显著增加全身不良事件风险(OR 1.17)。
- 血液毒性、血小板减少和高血压风险与对照组相似。
- 血栓形成风险显著增高(OR 3.23,95%CI 1.47-7.12),需监测并必要时抗凝。
核心结论
- 贝伐珠单抗联合伊立替康治疗恶性胶质瘤患者全身不良事件风险与对照组无显著差异。
- 血液毒性、血小板减少和高血压风险两组相似。
- 联合伊立替康组血栓形成风险更高。
研究设计与样本
- 系统综述与Meta分析,检索Cochrane Library、Embase和PubMed至2018年6月。
- 纳入6项研究,其中5项对照组为贝伐珠单抗单药或贝伐珠单抗联合替莫唑胺。
- 采用牛津循证医学中心证据等级(2009)、纽卡斯尔-渥太华量表星级系统和GRADE profiler评估证据质量。
主要发现
- 全身不良事件风险OR 1.17(95%CI 0.43-3.18)。
- 血液毒性OR 1.06(95%CI 0.26-4.38)。
- 血小板减少OR 1.07(95%CI 0.25-4.63)。
- 高血压OR 1.34(95%CI 0.28-6.36)。
- 血栓形成OR 3.23(95%CI 1.47-7.12)。
关键数值与推荐
- 全身不良事件OR 1.17(95%CI 0.43-3.18),无显著差异。
- 血液毒性OR 1.06(95%CI 0.26-4.38),无显著差异。
- 血小板减少OR 1.07(95%CI 0.25-4.63),无显著差异。
- 高血压OR 1.34(95%CI 0.28-6.36),无显著差异。
- 血栓形成OR 3.23(95%CI 1.47-7.12),联合组风险更高。
临床怎么用
- 对接受贝伐珠单抗联合伊立替康的恶性胶质瘤患者应监测血栓形成。
- 必要时给予抗凝治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Bevacizumab plus irinotecan is a new beneficial chemotherapy strategy for patients with malignant glioma. The purpose of this systematic review and meta-analysis was to comprehensively assess the risk of adverse vascular events in adults with malignant glioma treated with bevacizumab plus irinotecan. METHODS: The Cochrane Library, Embase and PubMed were searched, and relevant trials were identified up to June 2018. Two investigators screened all titles and abstracts for possible inclusion and extracted data independently. Six studies were included, and 5 of them in the control group using bevacizumab alone or bevacizumab with temozolomide. Three systems were used to assess the quality of evidence and the level of recommendation. The Oxford Centre for Evidence-Based Medicine Levels of Evidence (2009) system was used to classify the evidence into 5 levels (classes I-V). The star system from the Newcastle-Ottawa Scale was used to assess methodological quality. The GRADE profiler was used to evaluate the overall body of evidence. RESULTS: Our data show that bevacizumab plus irinotecan therapy does not significantly affect the risk of systemic adverse events (odds ratio [OR], 1.17; 95% confidence interval [CI], 0.43-3.18). Patients treated with bevacizumab plus irinotecan had a similar risk of hematotoxicity (OR, 1.06; 95% CI, 0.26-4.38), thrombocytopenia (OR, 1.07; 95% CI, 0.25-4.63), and hypertension (OR, 1.34; 95% CI, 0.28-6.36) compared with the control group (those treated without irinotecan). Thrombosis occurred more frequently in patients treated with bevacizumab plus irinotecan compared with the control group (OR, 3.23; 95% CI, 1.47-7.12). CONCLUSIONS: The risk of systemic adverse events was not significantly different between patients with malignant glioma treated with bevacizumab plus irinotecan and the control group. The risks of hematotoxicity, thrombocytopenia, and hypertension were similar in the 2 groups. The risk of thrombosis was higher in patients treated with bevacizumab plus irinotecan. Monitoring for thrombosis and administering anticoagulant therapy as necessary merit promotion for patients with malignant glioma receiving treatment with bevacizumab plus irinotecan.
引用
- Dong J, Meng X, Li S, et al. Risk of Adverse Vascular Events in Patients with Malignant Glioma Treated with Bevacizumab Plus Irinotecan: A Systematic Review and Meta-Analysis. World Neurosurg. 2019. PMID: 31203059. doi:10.1016/j.wneu.2019.06.043
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。